Olink Holding, which provides a platform of proteome analysis products for biomedical research, raised $353 million by offering 17.6 million ADS (25% secondary) at $20, above the range of $16 to $18. Certain entities advised by T. Rowe Price had indicated on $75 million worth of ADSs in the offering.
Olink provides a portfolio of protein biomarker analysis products, with its current offering based on a proprietary and patented Proximity Extension Assay (PEA) technology. PEA enables researchers to use one platform from discovery to clinical trials to diagnostic applications utilizing an established infrastructure of labs and installed instrumentation. Since inception, Olink has served a customer base of approximately 630 customer accounts in over 40 countries worldwide, supporting 30 of the world’s largest 40 biopharmaceutical companies by 2019 revenue, including all of the largest 19. The Olink platform has been used to generate more than 250 million protein biomarker target data points from approximately 2.3 million samples and its products have been used in studies published in over 500 peer-reviewed publications.
Olink Holding plans to list on the Nasdaq under the symbol OLK. Goldman Sachs, Morgan Stanley and SVB Leerink acted as lead managers on the deal.
